<DOC>
	<DOCNO>NCT01902992</DOCNO>
	<brief_summary>This study ass efficacy safety intraseasonal specific short-term immunotherapy Depiquick® Birch patient allergic rhinitis rhinoconjunctivitis without intermittent asthma clinical relevant IgE-mediated allergic sensitization birch pollen . The term `` intraseasonal '' mean patient start immunotherapy treatment birch pollen season , i.e . already experience allergic symptom .</brief_summary>
	<brief_title>Efficacy Safety Intraseasonal Specific Immunotherapy With Depiquick® Birch</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients must experience significant allergic symptom visit 2 2 . Medical history allergic rhinitis and/or rhinoconjunctivitis clinically relevant sensitization tree allergens 3 . Specific IgE birch allergen ( CAP RAST ≥ 2 ) Exclusion criterion : 1 . History significant clinical manifestation allergy result sensitization grass weed pollen perennial allergen 2 . FEV1 PEF value ≤ 80 % 3 . Persistent asthma ( GINA ≥ 2 ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>